solute carrier family 22 member 12Genealiases: OAT4L · RST · UAT · URAT1 · hURAT1
Q-omics provides the consensus-scored SLC22A12 profile across patient tissues and cancer cell-line models. SLC22A12 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SLC22A12 is differentially expressed in 8, with the highest sampling consensus in KIRP. Additionally, SLC22A12 RNA expression shows 8,188 significant protein co-abundance associations, with the highest sampling consensus in CCRCC. Together, these results highlight KIRC, KIRP, and CCRCC as cancer lineages where SLC22A12 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC22A12 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC22A12 survival associations across molecular data types. SLC22A12 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (7) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC22A12 RNA expression–survival associations across cancer types. High SLC22A12 expression shows unfavorable associations in CESC, COAD and CHOL, but favorable associations in KIRC, KIRP and SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SLC22A12 RNA expression.
This table summarizes SLC22A12 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for SLC22A12. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC22A12 shows lower tumor expression in KIRP, KIRC, KICH and BRCA and higher tumor expression in LIHC and COAD. The KIRP box plot shows higher SLC22A12 RNA expression in normal versus tumor tissue (log2 FC = −5.247, t-test p < 0.001).
This table shows molecular features associated with SLC22A12 in patient tissues and cancer cell lines. In patient samples, SLC22A12 shows the broadest associations at the RNA and protein expression levels, with CCRCC recurring as the lineage with the largest associated feature set. In cancer cell lines, SLC22A12 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in LIVER and BLOOD_Leukemia.
